

WE CLAIM:

1. A compound which is
 - 5 6-cyclopropaneamido-4- {[2-methoxy-3-(5-{1-[(2-methoxyethyl)carbamoyl]propyl}-1,2,4-oxadiazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide, (Ex 41)
 - 6-cyclopropaneamido-4-[(2-methoxy-3-{5-[1-(morpholin-4-yl)-1-oxopentan-2-yl]-1,2,4-oxadiazol-3-yl}phenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 10 42)
 - 6-cyclopropaneamido-4- {[2-methoxy-3-(5-{1-[(2-methoxyethyl)carbamoyl]butyl}-1,2,4-oxadiazol-3-yl)phenyl]amino}-N-(2H3)methylpyridazine-3-carboxamide, (Ex 43)
 - tert-butyl N-[(1R,2R)-2-(tert-butoxy)-1-{5-[3-({6-cyclopropaneamido-3-15 [(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}propyl]carbamate, (Ex 185)
 - 6-cyclopropaneamido-4-[(3-{3-[(1R,2R)-1-acetamido-2-hydroxypropyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 187)
 - 20 methyl N-[(1R,2R)-1-{5-[3-({6-cyclopropaneamido-3-[(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}-2-hydroxypropyl]carbamate, (Ex 188)
 - 6-cyclopropaneamido-4-[(3-{3-[(1R,2R)-2-hydroxy-1-propanamidopropyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 25 190)
 - tert-butyl N-[(1R)-2-(tert-butoxy)-1-{5-[3-({6-cyclopropaneamido-3-[(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}ethyl]carbamate, (Ex 193)
 - 6-cyclopropaneamido-4-[(3-{3-[(1R)-2-hydroxy-1-propanamidoethyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 30 198)

6-cyclopropaneamido-4-[(3-{3-[(1R)-1-acetamido-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 199)

5 (2R)-2-{5-[3-({6-cyclopropaneamido-3-[(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}-2-acetamidoethyl acetate, (Ex 200)

6-cyclopropaneamido-4-[(3-{3-[(1R)-2-hydroxy-1-(2-methoxyacetamido)ethyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 202)

10 6-cyclopropaneamido-4-[(3-{3-[(1S,2S)-1-acetamido-2-hydroxypropyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 203)

6-cyclopropaneamido-4-[(3-{3-[(1S,2S)-2-hydroxy-1-(2-methoxyacetamido)propyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 205)

15 tert-butyl N-[(1S,2S)-2-(tert-butoxy)-1-{5-[3-({6-cyclopropaneamido-3-[(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}propyl]carbamate, (Ex 206)

20 6-cyclopropaneamido-4-[(3-{3-[(1S,2S)-2-hydroxy-1-propanamidopropyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 208)

tert-butyl N-[(1S)-2-(tert-butoxy)-1-{5-[3-({6-cyclopropaneamido-3-[(2H3)methylcarbamoyl]pyridazin-4-yl}amino)-2-methoxyphenyl]-1,2,4-oxadiazol-3-yl}ethyl]carbamate, (Ex 219) or

25 6-cyclopropaneamido-4-[(3-{3-[(1S)-1-acetamido-2-hydroxyethyl]-1,2,4-oxadiazol-5-yl}-2-methoxyphenyl)amino]-N-(2H3)methylpyridazine-3-carboxamide, (Ex 220)

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising one or more compounds
30 according to any one of claim 1 and a pharmaceutically acceptable carrier or diluent.

3. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

4. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in treating an inflammatory or autoimmune disease.

5. The compound or a pharmaceutically acceptable salt thereof for use according to claim 4 wherein the inflammatory or autoimmune disease is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's Disease, Sjögren's syndrome or scleroderma.

6. Use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating an inflammatory or autoimmune disease.

7. The use of claim 6 wherein the inflammatory or autoimmune disease is multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's Disease, Sjögren's syndrome or scleroderma.